662-Hypoimmune CD19 CAR T Cells Evade Allorejection

Paper Talk · Mar 19, 2026 · 24m

This research report evaluates the SC291 hypoimmune (HIP) CD19 CAR T cell product, an allogeneic therapy engineered to treat cancers and autoimmune diseases without triggering patient rejection. By utilizing CRISPR-Cas editing to remove HLA markers and overexpress CD47, these specialized cells successfully bypassed both innate and adaptive immune responses in clinical trial participants. The study observed that while patients' immune systems attacked partially edited cells, the fully edited HIP CAR T cells remained protected and functionally active. Furthermore, researchers discovered that a…